Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganaplacide + lumefantrine - Medicines for Malaria Venture/Novartis

Next Previous
Drug Profile

Ganaplacide + lumefantrine - Medicines for Malaria Venture/Novartis

Alternative Names: GNF 156+lumefantrine; KAF 156+lumefantrine; KAF-156+Lumefantrine; KLU-156; Lumefantrine+GNF 156; Lumefantrine+KAF 156

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medicines for Malaria Venture; Novartis
  • Class Amines; Aniline compounds; Antimalarials; Antiprotozoals; Fluorobenzenes; Imidazoles; Ketones; Piperazines; Small molecules
  • Mechanism of Action Hemozoin inhibitors; Nucleic acid inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Falciparum malaria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Falciparum malaria

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Falciparum-malaria(In volunteers) in United Kingdom (PO)
  • 07 Mar 2024 Phase-III clinical trials in Falciparum malaria (In adolescents, In children, In infants, In adults) in India (PO), after March 2024 (NCT05842954)
  • 07 Mar 2024 Phase-III clinical trials in Falciparum malaria (In adults, In adolescents, In children, In infants) in Congo (PO) (NCT05842954)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top